Mukka Proteins Receives In-Principle Approval for Preferential Warrant Issue
Mukka Proteins received in-principle approval from NSE and BSE for issuing 2 crore convertible warrants to non-promoters on a preferential basis. The issue price is ₹23.50 per warrant. Approvals are subject to various regulatory compliances and conditions, including enhanced internal controls.
The preferential issue of warrants can impact the company's capital structure and potentially dilute existing shareholding. The approval is a step towards fundraising, but the actual impact depends on the successful completion of the allotment and conversion.
The company has received in-principle approval for a preferential issue of warrants, which is a positive development for fundraising and potential capital infusion.
Mukka Proteins Limited has received in-principle approval from both the National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) for the proposed issue and allotment of Convertible Warrants on a preferential basis to the Non-Promoter Category.
The approvals, dated August 28, 2026, are subject to compliance with SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, SEBI LODR Regulations, and other applicable laws. The company plans to issue 2,00,00,000 Convertible Warrants at an issue price of ₹23.50 each, with a face value of Re. 1/-
NSE and BSE have provided specific conditions that the company must fulfill, including filing the listing application promptly after allotment, obtaining all necessary statutory and regulatory approvals, and ensuring compliance with SEBI, RBI, MCA, and other applicable laws. The company is also advised to strengthen internal controls to monitor trades by proposed allottees and obtain undertakings from them to prevent intra-day trading and sales before the allotment date, as per SEBI (ICDR) Regulations.
A plain-language summary of a public exchange filing by Mukka Proteins Limited. Read the original for the full detail.